PreTarg-it® - Unlocking the Full Potential of Radioimmunotherapy
At OncoOne, we’re advancing cancer care with our innovative PreTarg-it® platform, which combines targeted antibodies and radiotherapy to treat challenging cancers more precisely while minimizing damage to healthy tissues.
PreTarg-it® - Target First. Treat Better.
Radiopharmaceutical therapies hold significant promise for cancer treatment, yet their clinical impact is often constrained by limited tumor selectivity and unintended radiation exposure to healthy tissues.
PreTarg-it® addresses this challenge by applying the principles of pretargeted radioimmunotherapy (PRIT). The approach deliberately separates tumor recognition from radioactive payload delivery, enabling precise tumor localization before radiation is administered. This controlled, two-step strategy improves targeting accuracy while minimizing exposure of healthy tissues to radioactivity.
At OncoOne, PreTarg-it® is developed as a focused oncology program designed to unlock the full potential of radiopharmaceutical therapies in hard-to-treat solid tumors. By combining antibody-based targeting with controlled radioligand delivery, the program aims to maximize therapeutic impact while supporting safe, translationally viable clinical development.
How the PreTarg-it® Platform Works
PreTarg-it® uses a two-step pretargeted radioimmunotherapy approach to control where and when radiation is delivered. A tumor-targeting bispecific antibody is first administered and allowed to accumulate at the tumor site, followed by clearance from circulation. A radiolabeled small molecule is then administered, binding selectively to the tumor-localized antibody and delivering radiation directly to the tumor while minimizing off-target exposure.
Our solution
Maximized Efficacy:
Reduces radiation exposure to healthy tissues.
Our Pipeline
Advancing Radioimmunotherapy with greater precision and protecting Healthy Tissue
We apply pretargeted radioimmunotherapy using a modular, antibody-based approach to treat with greater precision. Our modular PreTarg-it® platform supports multiple hard-to-treat cancer programs.
